GLG News by Cosmetic Dermatologists in Private Practice (US)

 The submission of Reloxin to the FDA is a positive sign for both Ipsen and Medicis. The market will only grow with the impending approval, and the launch of a competitor to Botox may result in some softening of pricing both to physicians and the end consumer. The two studies that have been done...

Meyer Pharmaceutical acquisition of a NF-kB decoy is interesting in that this would be the first new technology in this area since the topical immunomodulators like Protopic/ Elidel were released. The preliminary work looks good, and phase 2 trials in both atopic dermatitis and psoriasis would be necessary...

CombinatoRx new combination product- CRx-191 is intriguing in that it combines a topical steroid with nortryptiline to minimize the negative effects of the steroid and make it more potent. This would be useful in that higher potency topical steroids are more effective, but cause more thinning of the...

The recently announced collaboartion between Stiefel and Allergan in regards to Tazorac is very positive. Stiefel needs this molecule to put into different dosage forms, and in combination with its existing products espoecially Duac, etc. Their current acne product line is strong, but this will solodify...

Abbotts ABT-874 monoclonal antibody for psoriasis shows impressive results in the phase 2 trial. The results were up to 90% of patients achieving at least 75% reduction in their psoriasis. These results are as good or better than those with Remicade the most effective biologic for psoriasis currently....

The recent results for a trial of Relieva in atopic dermatitis or eczema, a cream containing a homeopathic compound, were positive by a report from the company. The study sample was small, and the trial was open label. Generally these trials have a larger number of patients, and are blinded. Also it...

This treatment is run illegally, in violation of FDA laws Additionally, it is outlawed in Europe, Canada and Brazil, among other places Lastly, it isn't all that effective, from what I hear, and very painful.  In summary, better options will become available.

 The FDA warning to Melanocorp regarding their product Melanotan was justified. These warnings are far too few and infrequent, and numerous companies make claims without studies or substantiation. The agency is overwhelmed with NDA's, and has difficulty handling the work that currently exists....

If a patient gets a bedsore, who pays for it? Most importantly, what does this mean to KCI and the other wound companies? Where will it end?

Lasers are better than they were 10 years ago.  Especially for vascular lesions; however, they are not all purpose machines that can do everything, as evidenced by new ones every year.